Quanterix Corp (QTRX)

Currency in USD
2.52
+0.01(+0.40%)
Closed·
2.47-0.05(-1.98%)
·
QTRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.432.60
52 wk Range
2.408.77
Key Statistics
Prev. Close
2.52
Open
2.56
Day's Range
2.43-2.6
52 wk Range
2.4-8.77
Volume
1.11M
Average Volume (3m)
1.06M
1-Year Change
-47.6091%
Book Value / Share
6.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QTRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.33
Upside
+71.96%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Quanterix Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Analyst Ratings

0 Buy
3 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 4.33
(+71.96% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Hold4.00+58.73%7.00MaintainMay 07, 2026
Canaccord
Hold4.00+58.73%8.00MaintainApr 20, 2026
Canaccord Genuity
Hold8.00+217.46%-MaintainJan 09, 2026
Canaccord Genuity
Hold8.00+217.46%5.00MaintainDec 22, 2025
Canaccord Genuity
Hold5.00+98.41%12.00DowngradeAug 11, 2025

Quanterix Corp Earnings Call Summary for Q1/2026

  • Q1 2026 EPS of -$0.37 beat estimates by 21.28%, but revenue of $36.4M missed forecasts by 2.2% amid 21% organic revenue decline YoY.
  • Akoya Biosciences integration delivered $85M in annualized cost synergies; diagnostics partner revenue nearly doubled YoY to $2.9M.
  • Stock rose 3.03% aftermarket to $3.40, though down 48% YTD, trading near 52-week low of $2.95 versus high of $8.77.
  • Maintained FY 2026 revenue guidance of $169M-$174M (~23% growth); expects Q4 cash flow breakeven with ~$100M cash by year-end.
  • Key risks include declining organic revenue in academic/pharma sectors, elevated operating expenses, and potential product launch delays.
Last Updated: 2026-05-06, 05:22 p/m
Read Full Transcript

Earnings

Latest Release
May 06, 2026
EPS / Forecast
-0.37 / -0.47
Revenue / Forecast
36.4M / 37.22M
EPS Revisions
Last 90 days

QTRX Income Statement

Compare QTRX to Peers and Sector

Metrics to compare
QTRX
Peers
Sector
Relationship
P/E Ratio
−1.1x−0.3x−0.5x
PEG Ratio
0.01−0.010.00
Price/Book
0.4x0.7x2.6x
Price / LTM Sales
0.8x3.3x3.1x
Upside (Analyst Target)
59.4%185.4%54.0%
Fair Value Upside
Unlock34.7%6.5%Unlock

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
16.09M34.18%40.38M
Other Institutional Investors
23.82M50.62%59.79M
Public Companies & Retail Investors
7.16M15.21%17.96M
Total
47.06M100.00%118.13M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Portolan Capital Management, LLC9.62%4,525,55311,404
BlackRock, Inc.7.17%3,375,9108,507

People Also Watch

22.865
REP
+0.59%
4.26
LFMD
-0.93%
19.345
BBVA
-0.57%
0.580
IPW
-27.05%
30.22
URGN
+6.94%

FAQ

What Is the Quanterix (QTRX) Stock Price Today?

The Quanterix stock price today is 2.52 USD.

What Stock Exchange Does Quanterix Trade On?

Quanterix is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Quanterix?

The stock symbol for Quanterix is "QTRX."

What Is the Quanterix Market Cap?

As of today, Quanterix market cap is 118.71M USD.

What Is Quanterix's Earnings Per Share (TTM)?

The Quanterix EPS (TTM) is -2.33.

When Is the Next Quanterix Earnings Date?

Quanterix will release its next earnings report on Aug 10, 2026.

From a Technical Analysis Perspective, Is QTRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Quanterix Stock Split?

Quanterix has split 0 times.

How Many Employees Does Quanterix Have?

Quanterix has 450 employees.

What is the current trading status of Quanterix (QTRX)?

As of May 21, 2026, Quanterix (QTRX) is trading at a price of 2.52 USD, with a previous close of 2.52 USD. The stock has fluctuated within a day range of 2.43 USD to 2.60 USD, while its 52-week range spans from 2.40 USD to 8.77 USD.

What Is Quanterix (QTRX) Price Target According to Analysts?

The average 12-month price target for Quanterix is 4.33 USD, with a high estimate of 5 USD and a low estimate of 4 USD. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +71.96% Upside potential.

What Is the QTRX Premarket Price?

QTRX's last pre-market stock price is 2.47 USD. The pre-market share volume is 170.00, and the stock has decreased by -0.05, or -1.98%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.